Values as of: 2024-11-13
COMMON STOCK | Biotechnology |
Last Closing
USD 80.48Change
-0.10 (-0.12)%Market Cap
USD 14.67BVolume
1.57MAnalyst Target
USD 106.20Verdict
Verdict
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
Company Website : https://www.incyte.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc |
+4.61 (+0.94%) |
USD 121.60B |
| REGN | Regeneron Pharmaceuticals Inc |
-16.67 (-2.03%) |
USD 92.70B |
| ARGX | argenx NV ADR |
+5.40 (+0.91%) |
USD 35.81B |
| ALNY | Alnylam Pharmaceuticals Inc |
-4.35 (-1.62%) |
USD 34.69B |
| BGNE | BeiGene Ltd |
+1.81 (+0.93%) |
USD 22.85B |
| MRNA | Moderna Inc |
-1.33 (-3.06%) |
USD 21.00B |
| UTHR | United Therapeutics Corporatio.. |
-0.42 (-0.10%) |
USD 16.70B |
| RPRX | Royalty Pharma Plc |
-0.15 (-0.58%) |
USD 16.11B |
| SMMT | Summit Therapeutics PLC |
-1.29 (-6.21%) |
USD 13.75B |
| PCVX | Vaxcyte Inc |
-2.75 (-2.77%) |
USD 13.28B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| IDNA | iShares Genomics Immunolo.. | 5.35 % | 0.00 % |
-0.24 (-0.38%) |
USD 0.15B |
| DXSI:XETRA | Xtrackers - Stoxx Europe .. | 4.65 % | 0.00 % |
-0.36 (-0.38%) |
USD 0.02B |
| XDNA:CA | iShares Genomics Immunolo.. | 4.44 % | 0.00 % |
-1.05 (-0.38%) |
CAD 5.26M |
| FBT:LSE | First Trust Global Funds .. | 3.79 % | 0.00 % |
+5.20 (+-0.38%) |
USD 8.45M |
| FBTU:LSE | First Trust Global Funds .. | 3.79 % | 0.00 % |
-0.06 (-0.38%) |
USD 8.45M |
| CURE:AU | ETFS S&P Biotech ETF | 2.62 % | 0.00 % |
-1.40 (-0.38%) |
USD 0.04B |
| SAGP | The Advisorsa Inner Circl.. | 2.14 % | 0.00 % |
-0.12 (-0.38%) |
USD 0.04B |
| BIS | ProShares UltraShort Nasd.. | 2.09 % | 0.95 % |
+0.24 (+-0.38%) |
USD 3.52M |
| HTEC | Robo Global® Healthcare .. | 1.94 % | 0.00 % |
-0.09 (-0.38%) |
USD 0.06B |
| DOCG:LSE | L&G Healthcare Breakthrou.. | 1.91 % | 0.00 % |
-0.50 (-0.38%) |
USD 0.07B |
| DOCT:LSE | L&G Healthcare Breakthrou.. | 1.91 % | 0.00 % |
-0.02 (-0.38%) |
USD 0.07B |
| MRND | 1.89 % | 0.00 % |
N/A |
N/A | |
| LABU | Direxion Daily S&P Biotec.. | 1.83 % | 1.14 % |
-2.08 (-0.38%) |
USD 0.99B |
| RSPH | Invesco S&P 500® Equal.. | 1.72 % | 0.00 % |
-0.09 (-0.38%) |
USD 0.90B |
| 2B77:F | iShares Ageing Population.. | 0.66 % | 0.00 % |
+0.05 (+-0.38%) |
N/A |
| FBT | First Trust NYSE Arca Bio.. | 0.00 % | 0.57 % |
+0.81 (+-0.38%) |
N/A |
| GURU | Global X Guru Index ETF | 0.00 % | 0.75 % |
-0.11 (-0.38%) |
N/A |
| PBE | Invesco Dynamic Biotechno.. | 0.00 % | 0.57 % |
+0.21 (+-0.38%) |
N/A |
| JSMD | Janus Henderson Small/Mid.. | 0.00 % | 0.50 % |
-0.73 (-0.38%) |
USD 0.38B |
| UBIO | 0.00 % | 0.95 % |
N/A |
N/A | |
| ZBIO | Zenas BioPharma, Inc. Com.. | 0.00 % | 0.95 % |
-1.51 (-0.38%) |
N/A |
| SIXL | 6 Meridian Low Beta Equit.. | 0.00 % | 0.00 % |
-0.09 (-0.38%) |
USD 0.18B |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 28.17% | 74% | C | 80% | B- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 28.17% | 74% | C | 79% | B- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 46.38% | 72% | C | 81% | B- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 46.38% | 72% | C | 80% | B- | ||
| Trailing 5 Years | |||||||
| Capital Gain | -7.17% | 69% | C- | 45% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -7.17% | 69% | C- | 38% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -9.93% | 33% | F | 21% | F | ||
| Dividend Return | -9.93% | 33% | F | 21% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 14.96% | 98% | N/A | 83% | B | ||
| Risk Adjusted Return | -66.35% | 17% | F | 11% | F | ||
| Market Capitalization | 14.67B | 99% | N/A | 95% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
